Skip to content
10-Q

Quarterly Report

ALSERES PHARMACEUTICALS INC /DE

0001193125-12-468653

← back to feed
Filed
Nov 14, 2012 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2012 · Oct 31, 2012 30.64M sh
Stock Repurchased Q3 2012 · Sep 30, 2012 $26.36K
Capex Q3 2012 · Sep 30, 2012 $1.65M
Capex Q3 2012 · Sep 30, 2011 $2.37K
Operating Cash Flow Q3 2012 · Sep 30, 2012 −$160.22M
Operating Cash Flow Q3 2012 · Sep 30, 2011 −$2.07M
Short Term Investments Q3 2012 · Sep 30, 2012 $880.26K
Short Term Investments Q3 2012 · Dec 31, 2011 $27.45K
Stockholders Equity Q3 2012 · Sep 30, 2012 −$32.1M
Stockholders Equity Q3 2012 · Dec 31, 2011 −$30.6M
Current Liabilities Q3 2012 · Sep 30, 2012 $15.48M
Current Liabilities Q3 2012 · Dec 31, 2011 $30.42M
Total Liabilities Q3 2012 · Sep 30, 2012 $32.75M
Total Liabilities Q3 2012 · Dec 31, 2011 $30.42M
Current Assets Q3 2012 · Sep 30, 2012 $953.36K
Current Assets Q3 2012 · Dec 31, 2011 $168.25K
Total Assets Q3 2012 · Sep 30, 2012 $1.02M
Total Assets Q3 2012 · Dec 31, 2011 $170.73K
Sga Expense Q3 2012 · Sep 30, 2012 $70.12M
Sga Expense Q3 2012 · Sep 30, 2011 $512.45K
Sga Expense Q3 2012 · Sep 30, 2011 $1.68M
Net Income Q3 2012 · Sep 30, 2012 −$198.23M
Net Income Q3 2012 · Sep 30, 2011 −$476.71K
Net Income Q3 2012 · Sep 30, 2011 −$2.09M
Operating Income Q3 2012 · Sep 30, 2012 −$196.41M
Operating Income Q3 2012 · Sep 30, 2011 −$536.88K
Operating Income restated Q3 2012 · Sep 30, 2011 −$1.23M
Revenue Q3 2012 · Sep 30, 2012 $1.41M
Cash And Equivalents Q3 2012 · Sep 30, 2011 $86.13K
Cash And Equivalents Q3 2012 · Dec 31, 2010 $98.51K